IN THE CLAIMS

Please cancel Claims 52-55.

Please amend the claims as follows:

4. (Four Times Amended) A method of treating an established staphylococcal infection of at least one organ or tissue selected from the group consisting of heart valve, blood, kidney, lung, bone and meninges, comprising systemically administering to a human suffering from at least one of said infections an effective amount of at least one recombinantly produced lysostaphin analogue;

wherein multiple doses of the lysostaphin analogue are administered and wherein the amount of lysostaphin analogue(s) administered is no more than 30 mg/kg/day.

5. (Four Times Amended) A method of treating an established infection associated with a catheter or a prosthetic device, comprising systemically administering to a human suffering from such an infection an effective amount of at least one recombinantly produced lysostaphin analogue;

wherein multiple doses of the lysostaphin analogue are administered and wherein the amount of lysostaphin analogue(s) administered is no more than 30 mg/kg/day.

41. (Twice Amended) The method of Claim 5, wherein the amount of lysostaphin analogue(s) administered is 0.5 mg/kg/day or more.

42. (Twice Amended) The method of Claim 32, wherein the amount of lysostaphin analogue(s) administered is 0.5 mg/kg/day or more.

43. (Twice Amended) The method of Claim 58, wherein the amount of lysostaphin analogue(s) administered is 0.5 mg/kg/day or more.

44. (Twice Amended) The method of Claim 4, wherein the amount of lysostaphin analogue(s) administered is no more than 25 mg/kg/day.

45. (Twice Amended) The method of Claim 5, wherein the amount of lysostaphin analogue(s) administered is no more than 25 mg/kg/day.

D3

46. (Twice Amended) The method of Claim 32, wherein the amount of lysostaphin analogue(s) administered is no more than 25 mg/kg/day.

47. (Twice Amended) The method of Claim 58, wherein the amount of lysostaphin analogue(s) administered is no more than 25 mg/kg/day.

D4

60. (Amended) The method of Claim 4, wherein the amount of lysostaphin analogue(s) administered is 0.5 mg/kg/day or more.

REMARKS

Support in the specification for the amendments to Claims 4 and 5 can be found at page 10, lines 5-12 and at page 23, Table 7.

The specification was objected to as failing to provide proper antecedent basis for the claimed subject matter. According to the Official Action, "[t]here is no description of the dosage ranges recited in claims 52-55" (see page 10, paragraph 6 of the Official Action).

As set forth above, the specification has been amended to recite the following:

> According to a preferred embodiment of the invention, the amount of lysostaphin analogue(s) administered is no more than 45 mg/kg/day.

Support for this amendment appears in original Claim 27. It is respectfully submitted that, in view of the above amendment, the objection to the specification has been obviated. Reconsideration and withdrawal of the objection to the specification is therefore respectfully requested.